拉米夫定联合阿德福韦酯治疗耐药株感染慢性乙型肝炎37例临床观察

摘要

目的 观察拉米夫定联合阿德福韦酯治疗耐药株感染慢性乙型肝炎患者的疗效.方法 耐拉米夫定慢性乙型肝炎患者11例换用阿德福韦酯,耐阿德福韦酯患者6例换用拉米夫定和耐拉米夫定28例/耐阿德福韦酯9例给予拉米夫定联合阿德福韦酯,观察治疗48周的疗效.结果 在治疗48周时,拉米夫定联合阿德福韦酯组患者血清HBV DNA阴转率(76%)和ALT复常率(92%)明显高于阿德福韦(45%,73%)和拉米夫定(50%,83%)治疗患者.结论 拉米夫定联合阿德福韦酯治疗耐药的慢性乙型肝炎患者,优于单用拉米夫定或阿德福韦酯治疗.%Objective To observe the effecr of lamivudine and adefovir combination therapy on patients with chronic hepatitis B. Methods 11 patients tolerated lamivudine switched to adefovir,6 tolerated to adefovir switched to lamivudine,and 28 tolerated lamivudine and 9 tolerated adefovir switched to lamivndine and adefovir combination therapy. Results At the end of 48 weeks therapy,the serum HBV DNA negative rate(76％)and ALT normalization rate(92％)in combination group were much higher than in adefovir(45％,73％)or lamivudine(50％,83％)groups. Conclusion The combination of lamivudine and adefovir therapy is an alternative option in hepatitis B patients tolerated to adefovir or lamivtudine.